A synthetic NKG2A engager enables long-term persistence of HLA-deficient allogeneic engineered Tregs.
An improved NKG2A engager is reported to selectively inhibit NKG2A⁺ NK cells while avoiding activation of NKG2C⁺ subsets, thereby overcoming a key limitation of the natural ligand HLA-E.